期刊文献+

阿立哌唑辅助氟伏沙明治疗难治性抑郁症的疗效分析 被引量:5

Efficacy of aripiprazole combined with fluvoxamine in the treatment of resistant depression
下载PDF
导出
摘要 目的:探讨阿立哌唑辅助氟伏沙明治疗难治性抑郁症的临床效果及安全性.方法:将58例难治性抑郁症患者随机分为研究组和对照组,各29例.对照组给予氟伏沙明(250 ~ 300 mg/d)治疗,研究组给予氟伏沙明(250 ~ 300 mg/d)联合阿立哌唑(2.5~7.5 mg/d)治疗.治疗观察期均为8周.两组患者于基线及治疗后1、2、4、8周末采用24项汉密尔顿抑郁量表(HAMD-24)评定治疗效果,并采用副反应量表(TESS)评定治疗期间的不良反应.结果:研究组在1、2、4、8周末的抑郁症状评分间差异均有统计学意义(P均<0.05);8周末时两组有效率差异有统计学意义(P<0.05),而不良反应发生率差异无统计学意义(P>0.05).结论:阿立哌唑辅助氟伏沙明治疗难治性抑郁症患者可持续、有效改善其抑郁症状,不良反应发生率与单用氟伏沙明治疗相当. Objective : To explore the efficacy and safety of aripiprazole combined with fluvoxamine in the treatment of resistant depression. Methods: 58 patients with resistant depression were ran- domly divided into study group and control group, 29 for each. Control group was treated with flu- voxamine(250-300 mg/d) while study group was treated with aripiprazole (2.5 -7.5 mg/d) combined with fluvoxamine (250 -300 mg/d). Each group had a 8-week course of treatment. The efficacy were assessed and analyzed by 24-item Hamilton Depression Scale (HAMD-24) at base- line,1,2,4 and 8 weeks after treatment. The side effects were assessed by Treatment Emergent Symptom Scale(TESS) during the treatment. Results: The scores of depressive symptoms in study group were statistically different at 1,2, 4 and 8 weeks after treatment(P 〈 0.05). The effective rates were statistically different in two groups(P 〈 0.05 ), while the occurrence rates of side effects had no statistical difference (P 〉 0.05 ). Conclusion: Aripiprazole combined with fluvoxamine can effectively improve the depressive symptoms in patients with resistant depression, the incidence rates of side effects was similar to single fluvoxamine therapy.
出处 《河南医学研究》 CAS 2014年第1期26-28,共3页 Henan Medical Research
关键词 阿立哌唑 氟伏沙明 难治性抑郁症 aripiprazole duloxetine resistant depression
  • 相关文献

参考文献5

  • 1世界卫生组织.ICD.10精神与行为障碍分类[M].范肖东,译.北京:人民卫生出版社.1993.
  • 2Delgado P L. Common pathways of depression and pain[ J]. J Clin Psychiatry, 2004, 65 (Suppl 12) : 16-19.
  • 3Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor[J]. Eur J Pharmacol, 2002, 441(3): 137-140.
  • 4陈晋东,赵靖平,李乐华,国效峰,吴仁容,翟金国,王传跃,谢世平,高成阁,丁瑛,陈远光.阿立哌唑治疗精神分裂症的多中心随机双盲对照试验[J].中国新药与临床杂志,2005,24(11):845-848. 被引量:65
  • 5Schatzberg A F, Arnow B A, Burt V K, et al. Depression and physi- cal symptoms: the mind-body connection [ J ]. J Clin Psychiatry, 2004, 65 ( 6 ) : 867-876.

二级参考文献5

  • 1KIKUCHI T,TOTTORI K, UWAHODO Y, et al. 7-(4-[4-(2,3-Dichlorophenyl) -1 -piperazinyl ] butyloxy ) -3, 4-dihydro-2 ( 1H ) -quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity [J]. J Pharmacol Exp Ther, 1995, 274( 1 ): 329-336.
  • 2McGAVIN JK, GOA KL. Aripiprazole [J]. CNS Drugs, 2002,16(11) :779-786.
  • 3SHAPIRO DA, RENOCK S, ARRINGTON E, et al. Aripiprazole,a novel atypical antipsychotic drug with a unique and robust pharmacology [ J ]. Neuropsychopharmacology, 2003, 28 (8): 1400-1411.
  • 4MARDER SR, McQUADE RD, STOCK E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term,placebo-controlled trials [ J ]. Schizophrt Res,2003,61 (2-3): 123-136.
  • 5KINGHORN WA, McEVOY JP. Aripiprazole: pharmacology, efficacy, safety and tolerability [ J]. Expert Rev Neurother, 2005, 5(3) :297-307.

共引文献65

同被引文献43

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部